RAPT Therapeutics

RAPT

Market cap $478M

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared RAPT's Investigational New Drug (IND) Application to proceed to a Phase 2b clinical trial of RPT904 for the treatment of patients with food allergy.

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in September:

The consensus price target hints at a 101% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

After reaching an important support level, Rapt Therapeutics (RAPT) could be a good stock pick from a technical perspective. RAPT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the second quarter and six months ended June 30, 2025.

The average of price targets set by Wall Street analysts indicates a potential upside of 122.2% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

FUTU, IVZ and RAPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2025.

The consensus price target hints at an 183.8% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

FUTU, PAAS, RAPT, HG and IVZ have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2025.